The multi‐centre phase II/III trial CCTG BR.36 enrolled previously untreated advanced NSCLC patients (EGFR/ALK‐wild‐type, PD‐L1 ≥ 50%). This evidence concerns the gene ALK and non-small cell lung carcinoma.